Literature DB >> 431401

A randomized comparative trial of three aminoglycosides--comparison of continuous infusions of gentamicin, amikacin and sisomicin combined with carbenicillin in the treatment of infections in neutropenic patients with malignancies.

M J Keating, G P Bodey, M Valdivieso, V Rodriguez.   

Abstract

Continuous infusions of gentamicin, amikacin or sisomicin combined with carbenicillin were compared in a randomized study in the treatment of 572 febrile episodes in 281 patients with cancer. The three treatments (C+A, C+A and C+S) were equally effective with no significant differences in response rate overall (67%, 68%, 67%) or in any infection, except septicemia where C+G had a significantly lower response rate than the other two groups. Pneumonia, the most common infection, had the lowest response rate for all three groups (45-50%). Klebsiella spp. were the most common pathogens and showed a lower response rate than other gram-negative bacilli (P = 0.003). Patients with persistent severe neutropenia had a response rate of 56%. Azotemia was significantly less common in patients with documented infection treated with C+A than in the C+S group. Combinations of carbenicillin plus an aminoglycoside antibiotic are effective for the treatment of infections in neutropenic patients.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 431401     DOI: 10.1097/00005792-197903000-00004

Source DB:  PubMed          Journal:  Medicine (Baltimore)        ISSN: 0025-7974            Impact factor:   1.889


  23 in total

Review 1.  A review of drug prescribing in children with end-stage renal failure.

Authors:  R S Trompeter
Journal:  Pediatr Nephrol       Date:  1987-04       Impact factor: 3.714

Review 2.  Role of pharmacokinetics in the outcome of infections.

Authors:  G L Drusano
Journal:  Antimicrob Agents Chemother       Date:  1988-03       Impact factor: 5.191

3.  Imipenem or cefoperazone-sulbactam combined with vancomycin for therapy of presumed or proven infection in neutropenic cancer patients.

Authors:  G Bodey; D Abi-Said; K Rolston; I Raad; E Whimbey
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1996-08       Impact factor: 3.267

4.  Enhanced in vitro bactericidal activity of amikacin or gentamicin combined with three new extended-spectrum cephalosporins against cephalothin-resistant members of the family Enterobacteriaceae.

Authors:  A S Bayer; R Eisenstadt; J O Morrison
Journal:  Antimicrob Agents Chemother       Date:  1984-06       Impact factor: 5.191

Review 5.  Sisomicin, netilmicin and dibekacin. A review of their antibacterial activity and therapeutic use.

Authors:  P Noone
Journal:  Drugs       Date:  1984-06       Impact factor: 9.546

6.  Double beta-lactam regimen compared to an aminoglycoside/beta-lactam regimen as empiric antibiotic therapy for febrile granulocytopenic cancer patients.

Authors:  J H Joshi; K A Newman; B W Brown; R S Finley; R L Ruxer; M A Moody; S C Schimpff
Journal:  Support Care Cancer       Date:  1993-07       Impact factor: 3.603

Review 7.  Antibacterial therapy in patients with malignancies.

Authors:  K H Mayer; S M Opal
Journal:  Cancer Metastasis Rev       Date:  1987       Impact factor: 9.264

8.  Treatment of gram-negative bacillary septicemia with cefoperazone.

Authors:  H Lagast; F Meunier-Carpentier; J Klastersky
Journal:  Eur J Clin Microbiol       Date:  1983-12       Impact factor: 3.267

9.  In vitro and in vivo studies of three antibiotic combinations against gram-negative bacteria and Staphylococcus aureus.

Authors:  S H Zinner; J Klastersky; H Gaya; C Bernard; J C Ryff
Journal:  Antimicrob Agents Chemother       Date:  1981-10       Impact factor: 5.191

10.  Ceftazidime sodium carbonate versus ceftazidime arginine as empirical monotherapy in febrile neutropenic patients.

Authors:  C Verhagen; B E De Pauw; K J Williams; W Du Bois
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1988-04       Impact factor: 3.267

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.